Royal Sense Ltd
Founded in 2023, Royal Sense Limited deals in Medical Equipment, Surgical Instruments, Surgical Consumables, Laboratory Equipment, Laboratory Reagents, Medical Disposables and Diagnostic Kits.[1]
- Market Cap ₹ 160 Cr.
- Current Price ₹ 299
- High / Low ₹ 307 / 104
- Stock P/E 54.4
- Book Value ₹ 41.3
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Stock is trading at 7.23 times its book value
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Jun 2023 3m | Sep 2023 6m | Mar 2024 | TTM | |
|---|---|---|---|---|
| 4.64 | 8.03 | 18.96 | 22.00 | |
| 3.95 | 7.09 | 16.59 | 18.01 | |
| Operating Profit | 0.69 | 0.94 | 2.37 | 3.99 |
| OPM % | 14.87% | 11.71% | 12.50% | 18.14% |
| 0.00 | 0.01 | 0.03 | 0.06 | |
| Interest | 0.00 | 0.00 | 0.09 | 0.10 |
| Depreciation | 0.00 | 0.00 | 0.01 | 0.01 |
| Profit before tax | 0.69 | 0.95 | 2.30 | 3.94 |
| Tax % | 26.09% | 26.32% | 26.09% | |
| 0.51 | 0.70 | 1.70 | 2.94 | |
| EPS in Rs | 1.48 | 2.03 | 3.47 | 6.00 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Jun 2023 | Sep 2023 | Mar 2024 | Sep 2024 | |
|---|---|---|---|---|
| Equity Capital | 3.45 | 3.45 | 4.90 | 4.90 |
| Reserves | 0.51 | 0.70 | 13.44 | 15.35 |
| 0.27 | 0.28 | 1.61 | 1.55 | |
| 2.08 | 1.27 | 0.93 | 1.37 | |
| Total Liabilities | 6.31 | 5.70 | 20.88 | 23.17 |
| 0.04 | 0.04 | 0.05 | 0.06 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.04 | 0.04 | 0.43 | 0.44 |
| 6.23 | 5.62 | 20.40 | 22.67 | |
| Total Assets | 6.31 | 5.70 | 20.88 | 23.17 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Jun 2023 | Sep 2023 | Mar 2024 | |
|---|---|---|---|
| -2.24 | 0.40 | -0.81 | |
| -0.08 | 0.00 | -3.73 | |
| 3.45 | 0.01 | 13.13 | |
| Net Cash Flow | 1.12 | 0.40 | 8.59 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Jun 2023 | Sep 2023 | Mar 2024 | |
|---|---|---|---|
| Debtor Days | 317.80 | 58.18 | 90.48 |
| Inventory Days | 68.13 | 71.68 | 6.27 |
| Days Payable | 177.15 | 47.42 | 1.16 |
| Cash Conversion Cycle | 208.79 | 82.44 | 95.59 |
| Working Capital Days | 236.78 | 178.64 | 145.35 |
| ROCE % |
Documents
Announcements
-
Intimation Pursuant To Regulation 30 Of The SEBI (LODR) Regulations, 2015 Regarding Launch Of New Product
21 Nov - Royal Sense Limited launches new pharmaceutical products.
-
Announcement under Regulation 30 (LODR)-Allotment
20 Nov - Allotment of 4,50,000 convertible warrants to non-promoters.
-
Board Meeting Outcome for Outcome Of The Board Meeting Held Today I.E., On 20Th November, 2024 In Terms Of
Regulation 30 Of The SEBI (Listing Obligations And Disclosure
Requirements) Regulations, 2015
20 Nov - Allotment of 4,50,000 convertible warrants to non-promoters.
-
Intimation Under Regulation 30 Of SEBI (LODR) Regulations, 2015-Application Submission For License/U.S. FDA Certification
16 Nov - Applied for U.S. FDA Certification for medical devices.
-
Appointment of Company Secretary and Compliance Officer
15 Nov - Appointment of Company Secretary and opening of new facilities.
Business Profile[1] Royal Sense Ltd. (RSL) supplies materials to hospitals, laboratories, institutions and clinics for health services.